A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology

Abstract

Non-invasive, immuno-dynamic, biomarkers positioned in cancer patient’s blood milieu with immuno-oncological applications are rare. We recently established a “first-in-class” serum functional immunodynamics status (sFIS) assay, wherein in vitro assessment of serum-induced myeloid NFkB and/or interferon (IFN) response-signaling can be performed to “mimic” in situ patient’s serum immune-biology. This modality has clear implications for anticipating patient prognosis and immunotherapy-relevant stratification.

Keywords

• immunosurveillance
• anticancer immunity
• inhibitory receptors
• lymphocytes
• benign or borderline lesions
• immunology
• neutrophils
• wound healing
• tgfb1
• pattern-recognition receptors (prrs)
• ovarian canc er